Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair Proficient Colorectal Cancer

0
113
Researchers investigated whether LAG-3/PD-1 inhibition would improve clinical outcomes in a mismatch repair proficient colorectal cancer subset.
[Clinical Cancer Research]
Abstract